share_log

Evercore ISI Group Maintains Outperform on Jasper Therapeutics, Maintains $65 Price Target

Benzinga ·  Aug 27 00:32  · Ratings

Evercore ISI Group analyst Gavin Clark-Gartner maintains Jasper Therapeutics (NASDAQ:JSPR) with a Outperform and maintains $65 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment